Monday, February 6 2012 4:05 PM EST2012-02-06 21:05:06 GMT
Chris Test 1Chris Test 1Chris Test 1Chris Test 1Chris Test 1Chris Test 1Chris Test 1Chris Test 1Chris Test 1Chris Test 1Chris Test 1More >>
Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.
SOURCE Egenix, Inc.
MILLBROOK, N.Y., Oct. 23, 2013 /PRNewswire/ -- Donald Fresne, President and CEO of Egenix, Inc. is pleased to announce the appointment of Matthew Fury, M.D., Ph.D. to its Scientific Advisory Committee.
Dr. Fury is a Medical Oncologist in The Department of Medicine at Memorial Sloan-Kettering. Since 2006 Dr. Fury has been conducting clinical research focused on mTOR/eIF4E inhibitors for Human Papilloma related head and neck cancers. He will now be participating in a collaboration with Egenix in the development of a drug for HPV.
We at Egenix are delighted to have Dr. Fury aboard.
Egenix is a privately held, New York-based biotechnology company focused on the development of innovative cancer therapeutics. The company's therapeutic platform technology consists of small molecule drugs applicable for the treatment and prevention of a broad spectrum of cancers, autism, and Alzheimer's. Our lead drug candidates inhibit the "translation initiation factor" eIF4E, specifically blocking production of multiple cancer promoting proteins and promoting apoptosis (programmed cell death) and upregulation of tumor suppressor genes. The company licensed this technology from Harvard Medical School in 2007. eIF4E is an attractive cancer therapeutic target because every function necessary for cancer growth and metastasis is influenced or mediated be a gene product that is regulated by this translation initiation factor. Data from human cancer xenograft studies using two of our lead compounds tested against breast cancer and melanoma demonstrated 100% tumor inhibition and 20% to 30% tumor reduction. For more information visit www.egenixinc.com.